Marc C Smaldone
Overview
Explore the profile of Marc C Smaldone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
244
Citations
2733
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Handorf E, Smaldone M, Movva S, Mitra N
Biom J
. 2022 Dec;
66(1):e202200099.
PMID: 36541715
One of the most common ways researchers compare cancer survival outcomes across treatments from observational data is using Cox regression. This model depends on its underlying assumption of proportional hazards,...
12.
Ginsburg K, Castro Bigalli A, Schober J, Perlman D, Handorf E, Chen D, et al.
Urol Oncol
. 2022 Jun;
40(10):455.e19-455.e25.
PMID: 35725937
Objectives: To investigate the association of surgical approach with outcomes in patients with adrenocortical carcinomas smaller and larger than 6 cm in size. Methods: We reviewed the national cancer database...
13.
Ginsburg K, Chandra A, Handorf E, Schober J, Mahmoud A, Smaldone M, et al.
Clin Genitourin Cancer
. 2022 May;
20(5):497.e1-497.e7.
PMID: 35618598
Microabstract: In the National Cancer Database (NCDB), patients treated with minimally invasive adrenalectomy (MIA) for adrenocortical carcinoma (ACC) had similar oncological outcomes and cumulative treatment burden with less morbidity compared...
14.
Di Maida F, Campi R, Lane B, de Cobelli O, Sanguedolce F, Hatzichristodoulou G, et al.
J Clin Med
. 2022 Apr;
11(7).
PMID: 35407375
Background: To explore predictors of positive surgical margins (PSM) after robotic partial nephrectomy (PN) in a large multicenter international observational project, harnessing the Surface-Intermediate-Base (SIB) margin score to report the...
15.
Campi R, Grosso A, Lane B, de Cobelli O, Sanguedolce F, Hatzichristodoulou G, et al.
Minerva Urol Nephrol
. 2022 Mar;
74(2):186-193.
PMID: 35345387
Background: Over the years, five different Trifecta score definitions have been proposed to optimize the framing of "success" in partial nephrectomy (PN) field. However, such classifications rely on different metrics....
16.
Ghatalia P, Handorf E, Geynisman D, Deng M, Zibelman M, Abbosh P, et al.
J Urol
. 2022 Feb;
208(1):71-79.
PMID: 35212574
Purpose: The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) was challenged by the results of the CARMENA trial. Here we evaluate the role of CN in...
17.
Campi R, Di Maida F, Lane B, de Cobelli O, Sanguedolce F, Hatzichristodoulou G, et al.
Eur J Surg Oncol
. 2021 Dec;
48(3):687-693.
PMID: 34862095
Introduction: We aimed to compare the outcomes of open vs robotic partial nephrectomy (PN), focusing on predictors of Trifecta failure in patients with highly complex renal masses. Patients And Methods:...
18.
Ginsburg K, Chandra A, Schober J, Handorf E, Uzzo R, Greenberg R, et al.
Urol Oncol
. 2021 Jul;
39(11):791.e1-791.e7.
PMID: 34301459
Objectives: To test for an association between oncological risk factors and overall survival in patients with non-metastatic adrenocortical carcinoma treated with adjuvant radiation therapy at high-risk for recurrence per NCCN...
19.
Srivastava A, Uzzo R, Lee J, Cho E, Grieco A, Masic S, et al.
Urol Oncol
. 2021 Jul;
39(11):790.e9-790.e15.
PMID: 34301455
Introduction And Objectives: Renal mass biopsy (RMB) has not been widely adopted in evaluating small renal mass due to concerns for safety, efficacy, and its perceived lack of consequence on...
20.
Bernstein A, Talwar R, Handorf E, Syed K, Danella J, Ginzburg S, et al.
JAMA Oncol
. 2021 Jul;
7(10):1467-1473.
PMID: 34292311
Importance: Early in the COVID-19 pandemic, racial/ethnic minority communities disproportionately experienced poor outcomes; however, the association of the pandemic with prostate cancer (PCa) care is unknown. Objective: To assess the...